U.S., Jan. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07319975) titled 'Effect of Semaglutide and Tirzepatide Combined With Exercise in Obesity' on Dec. 07, 2025.
Brief Summary: Obesity is a growing global health problem that affects people of all ages. It can lead to serious health issues such as cardiovascular disease, insulin resistance, inflammation, and reduced physical function. New medications, including GLP-1 receptor agonists like semaglutide and dual GLP-1/GIP agonists like tirzepatide, have been shown to help people lose significant weight. However, some of this rapid weight loss may come from a reduction in muscle mass rather than fat. Losing muscle can lower physical performance, impair meta...